Healthcare shares are flat in pre-market. Biota Pharmaceuticals
) said its Q4 loss narrowed to $0.23 per share from $0.26 the year
earlier, even as total net loss widened to $6.5 million from $5.9
million the year earlier.
Revenue increased in the quarter to $9.3 million from $7.1
million, primarily because of a $4.6 million increase in service
revenue related to the advancement of laninamivir octanoate into a
phase 2 clinical trial, offset in part by a decrease of $2.2
million in royalty revenue from net sales of Relenza and
And, Sangamo BioSciences, Inc. (
) shares are down 2% pre-market after the company announced it
intends to offer and sell shares of its common stock in an
underwritten public offering.
Terms of the offering are still unknown at this point, as it is
subject to market conditions. All of the shares in the offering are
to be sold by Sangamo.
Finally, Prima Biomed Ltd. (
) reported top-line analysis of the CAN-003 phase 2 study of CVac
for treatment of epithelial ovarian cancer patients in first or
The company said the results demonstrate that CVac was generally
well tolerated, with no Serious Adverse Events considered related
to protocol therapy. The majority of non-Serious Adverse Events
were considered mild and transient in nature. PBMD is flat
pre-market at $2.35.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.